论文部分内容阅读
目的探讨三维适形放射治疗同步顺铂或奈达铂化疗治疗中晚期宫颈癌的疗效及不良反应。方法 2006年10月至2008年3月收治的60例中晚期宫颈癌患者,采用随机数字法分为奈达铂组(30例)和顺铂组(30例),外照射采用盆腔四野盒式照射,95%PTV 45~50Gy,每次1.8~2Gy分25次,后装治疗采用192Ir后装治疗机,A点剂量36~42Gy,每次6Gy分6~7次。奈达铂组给予奈达铂每周30mg/m2,顺铂组给予顺铂每周30mg/m2,放射治疗第1、8、15、22、29、36天给药。结果两组患者有效率均达100%。奈达铂组患者完全缓解率为83.3%,顺铂组为73.3%(P>0.05)。两组患者3年总生存率差异无统计学意义。奈达铂组患者胃肠道反应(X2=7.445,P<0.05)和肾功能损伤(X2=5.420,P<0.05)明显低于顺铂组,而血小板下降发生率明显高于顺铂组(X2=9.320,P<0.05),但主要为Ⅰ/Ⅱ级。结论奈达铂或顺铂联合同步放射治疗治疗中晚期宫颈癌疗效相似,但奈达铂的耐受性优于顺铂。
Objective To investigate the efficacy and adverse effects of three-dimensional conformal radiotherapy (CIDT) or nedaplatin chemotherapy for advanced cervical cancer. Methods Sixty patients with advanced cervical cancer who were admitted to our hospital from October 2006 to March 2008 were divided into Nedaplatin group (30 cases) and cisplatin group (30 cases) by random number method. Exposure, 95% PTV 45 ~ 50Gy, each divided into 25 times 1.8 ~ 2Gy, after treatment using 192Ir after-treatment machine, A dose 36 ~ 42Gy, 6Gy each 6 to 7 times. The nedaplatin group was treated with nedaplatin 30mg / m2 weekly, cisplatin 30mg / m2 cisplatin weekly, and radiation therapy days 1,8,15,22,29,36. Results The effective rate of both groups reached 100%. The complete remission rate was 83.3% in the nedaplatin group and 73.3% in the cisplatin group (P> 0.05). There was no significant difference in 3-year overall survival between the two groups. The gastrointestinal reactions (X2 = 7.445, P <0.05) and renal dysfunction (X2 = 5.420, P <0.05) in the nevirapine group were significantly lower than those in the cisplatin group, while the incidence of thrombocytopenia was significantly higher than that in the cisplatin group 9.320, P <0.05), but mainly Ⅰ / Ⅱ grade. Conclusion The efficacy of nedaplatin or cisplatin combined with concurrent radiotherapy in the treatment of advanced cervical cancer is similar, but the toxicity of nedaplatin is better than that of cisplatin.